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Abstract
Background
Approximately 11% of people reported to have tuberculosis (TB) have previously received
treatment. Clinical outcomes are consistently poor on retreatment regimens, however rea-
sons for this are unclear. This study aimed to explore factors which may contribute to unsuc-
cessful outcomes in retreatment TB.
Methods and findings
A prospective cohort of consecutive patients starting WHO Category II retreatment regimen
was recruited at a central hospital in Malawi. Participants were evaluated at baseline, after
completion of the intensive phase at 2-months, and at the end of the 8-month treatment
course. Patients were assessed for respiratory co-morbidity; anaemia; renal impairment; dia-
betes; Anti-retroviral (ART) failure; and drug toxicity. Amongst 158 patients entering TB care
at the point of a recurrent episode, only 92 (58%) had a microbiologically confirmed diagno-
sis. The prevalence of drug resistance was low (9.6%). Of the 158 patients, 131 (83%) were
HIV-positive, of whom 96 (73%) were on ART. Of 63 patients on ART >1 year, 24 (38%) had
ART failure. Chronic lung disease was found in 88% on CT thorax, including scarring (80%),
bronchiectasis (61%), COPD (22%), and destroyed lung (19%). Spirometry revealed restric-
tive deficit in 60%, and obstructive deficit in 7% of patients. Anaemia and renal impairment
were common (34% and 45% respectively). Ototoxicity developed in 32%, and nephrotoxicity
in 15%. 40% of patients reported peripheral neuropathy. Liver injury developed in 4%.
Conclusions
If outcomes are to be improved in retreatment TB, there is an urgent need to address the
impact of other co-morbid medical conditions including chronic lung disease, HIV and ART
failure.
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Introduction
Each year, approximately 11% of all people reported to have tuberculosis (TB) have previously
received treatment, which in 2016 amounted to 0.6 million people [1]. Although it accounts
for a minority of those treated for TB, retreatment TB is associated with a disproportionate
burden for patients, families and health systems.
Patients with ‘retreatment TB’ form a heterogeneous group of people who have previously
been treated for TB. They comprise those with microbiologically confirmed relapse after suc-
cessful treatment; treatment failure (defined as remaining smear or culture positive after 5
months of treatment); treatment following loss to follow-up; and people classified as ‘other’
who have had previous treatment but do not fulfil any of the other definitions [2]. In 1991, The
World Health Organization (WHO) recommended that people presenting with TB in settings
with a low prevalence of multidrug-resistant TB (MDR-TB) who have previously been treated
were prescribed a standardised regimen consisting of Rifampicin(R), Isoniazid(H), Pyrazina-
mide(Z), Ethambutol(E) and Streptomycin(S) for 2 months, followed by RHZE for 1 month
and then RHE for 5 months [3]. This ‘Category II’ regimen has no clinical trial evidence base,
and treatment outcomes in this group of patients are persistently reported to be poor [4–7].
The most recent WHO TB treatment guidelines therefore recommend discontinuation of the
Category II regimen where possible in favour of regimens which are guided by the results of
drug susceptibility testing (DST) [8].
Whilst it is often assumed that poor outcomes are due to the increased prevalence of drug
resistance in this group, rates of successful treatment are sub-optimal even in regions where
the prevalence of drug resistance is low and when those with rifampicin resistance are treated
with second line agents [1]. A study in Zimbabwe suggested that there is a significant burden
of chronic lung disease in patients on TB retreatment, and that empirical treatment for TB
may be masking a bigger problem of chronic lung disease [9], but no research has comprehen-
sively addressed the reasons for poor treatment outcomes in patients accessing care at the
point of a second TB episode.
We conducted a prospective study in Malawi of patients presenting with TB who had previ-
ously received treatment. The aim of the study was to evaluate the problem of poor outcomes
in patients with retreatment TB by examining the burdens of drug resistance, medical co-mor-
bidity and drug toxicity in patients prescribed TB retreatment.
Methods
Study design and participants
Queen Elizabeth Central Hospital is the largest hospital in Malawi, treating approximately
2000 patients for tuberculosis each year. All patients with retreatment tuberculosis in the Blan-
tyre district are referred for management. At the time of the study, all retreatment patients in
Malawi were prescribed the standard WHO category II regimen. A prospective descriptive
study was conducted in which consecutive adult patients being registered with retreatment
tuberculosis over a 15-month time period were recruited. The rate of successful treatment for
‘new’ (non-retreatment) patients in Malawi during the period of the study was 85% [10].
Patients were included in the study if they were�16 years old and able to provide informed
consent. Patients were excluded if they had MDR-TB identified on drug sensitivity testing or
rifampicin resistance detected using molecular techniques. All participants provided written
(or, in the case of those who were illiterate, witnessed) informed consent. Ethical approval for
the study was obtained from The Malawi College of Medicine and The Liverpool School of
Tropical Medicine.
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Procedures
Patients were assessed during routine TB follow-up visits at baseline, two months and comple-
tion of treatment.
Laboratory procedures. Laboratory tests were carried out at the Malawi-Liverpool-Well-
come Research Programme, Malawi College of Medicine (Blantyre) or University of North
Carolina laboratory (Lilongwe). Serum creatinine, ALT and bilirubin were measured using
Beckman Coulter Synchron CX5 PRO Clinical System. Kidney injury was defined as increase
in creatinine of 1.5-fold, or reduction in CrCl by�25%. Renal impairment was defined as cre-
atinine >115μmol/L or CrCl<90 mL/min. Drug induced liver injury was diagnosed if ALT
>200 IU/L; rise in bilirubin to>40 μmol/L; or clinical jaundice [11–13]. Full blood count was
performed using Beckman Coulter HmX analyser. Anaemia was defined as Hb <8g/dL [14].
HbA1c was performed using AU480 Beckman Coulter analyser. Diabetes was diagnosed if
HbA1c�6.5% [15].
In HIV-positive patients, CD4 count was performed using CyFlow Counter (Sysmex Par-
tecGmbH, Gorlitz, Germany). HIV viral load (VL) was performed using Abbott m2000 Real-
Time System (Illinois, USA) in patients who had been on ART > one year. ART failure was
diagnosed using the standard operational definition in Malawi (HIV VL>5000 copies/ml).
Sputum samples were stained with Auramine-O and examined using florescence micros-
copy. Liquid culture was performed using BACTEC MGIT 960 Mycobacterial Detection Sys-
tem (Becton, Dickinson and Company, New Jersey, USA). XpertMTB/RIF assay (Cepheid
Sunnyvale, USA) was performed on unprocessed sputum samples according to manufacturer’s
instructions. Microbiologically confirmed TB was defined as sputum smear, culture or
XpertMTB/RIF positive. Successful treatment was defined as a combination of ‘cured’ and
‘treatment completed’ [2].
Radiology. Chest radiographs were performed at the start of treatment at the QECH
department of radiology. In a subgroup, Computerised Tomography (CT) thorax was per-
formed during the first two months of treatment. The CT scanner in Blantyre was not func-
tional at the start of the study, and CT was performed on consecutive patients once it was
available. CT was performed on a SOMATON Sensation 16 slice scanner (Siemens) using the
pre-programmed, low dose, unenhanced lung protocol. Images were reviewed using Osir-
iX-HD software. Two radiologists independently reported all images, followed by a consensus
approach to resolve discrepancies on final diagnosis. All reports were recorded on standard-
ised proformae developed from established guidelines [16].
Audiology. Audiological assessments were done at baseline, 2 months and 8 months. Oto-
scopy was performed to exclude abnormality in the auditory canal or tympanic membrane.
Pure Tone Audiometry (PTA) was performed using the KUDUwave 5000 audiometer
(eMoyoDotnet (Pty) Ltd, Randburg, South Africa). PTA thresholds were obtained at frequen-
cies of 250–1600 kHz. In line with guidelines [17–18] significant change in hearing was defined
as�20 dB change from baseline at any one test frequency; or�10 dB change from baseline at
two consecutive frequencies. To improve specificity for ototoxicity, this definition was refined
to include only change in hearing at high frequency (�8000 kHz). Vestibular assessment
included Romberg’s test, head thrust test, and clinical test of sensory integration of balance.
Lung function. Spirometry was performed on patients at 2 and 8 months using the Easy-
One spirometer (ndd Medical Technologies, MA, USA), according to manufacturer’s instruc-
tions. Spirometry was performed at 2-months rather than at baseline in order to obtain an
accurate evaluation of underlying lung function after resolution of the acute episode; and
because of infection control concerns. Results were compared to predicted levels using
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NHANES III reference ranges. For quality control, a second reader reviewed 20% of all tests.
Interpretation of spirographs was based on the GOLD criteria [19].
Statistical analysis
This was a descriptive study recruiting consecutive patients over a defined time period and
therefore not based on sample size calculation. Exploratory analyses were performed to evalu-
ate possible associations with clinical outcome using multivariate logistic regression models
with predefined variables.
Results
Between June 2013 and September 2014, 158 patients were enrolled (Fig 1). Baseline character-
istics of the study population are shown in Table 1.
Tuberculosis factors
Only 92/158 (58%) had a microbiologically confirmed diagnosis and most (53.2%) of patients
were classified as ‘other’. There were no significant associations between microbiologically
confirmed TB and age, gender, HIV, chronic lung disease or diabetes. From patients who were
sputum culture positive, fifty-two isolates were recovered for phenotypic drug sensitivity test-
ing. There were no significant associations between having had DST performed and gender,
HIV status, the presence of chronic lung disease or abnormal spirometry. After screening for
rifampicin resistance with GeneXpert, there was no undiagnosed rifampicin resistance. Spu-
tum from only five patients (9.6%) cultured M. tuberculosis isolates with drug resistance (3 eth-
ambutol resistance; 2 isoniazid resistance).
HIV factors
HIV prevalence was 82.9% (compared to 56% HIV prevalence reported in ‘new’ TB patients in
Malawi at the time of the study [20]); and the median CD4 count of HIV-positive patients was
171 cells/mm3. There were 63 patients who had been on ART >1 year, and 24 (37.5%) of these
had ART failure.
Other co-morbidities
Whilst baseline anaemia and renal impairment were common (22.2% and 33.8% respectively),
diabetes was present in only 3.3% of patients. Of 102 patients who had CT thorax performed,
88 (86.3%) had chronic lung disease. Bronchiectasis was present in 62 patients; features of
emphysema in 22; scarring in 20; and destroyed lung in 19. There were no significant differ-
ences in the rates of chronic lung disease between those patients who were sputum culture pos-
itive and those who were sputum culture negative. The majority (71%) of bronchiectasis was
cystic bronchiectasis. Patients with bronchiectasis on CT were more likely to have changes
consistent with acute pulmonary disease on chest x-ray than those without bronchiectasis
(95.2% v 71.1%, p-value 0.002). Of 62 patients with bronchiectasis on CT thorax, 32 (52%) had
no evidence of bronchiectasis on plain chest x-ray. After adjusting for age, gender, smoking,
HIV and confirmed TB, bronchiectasis was associated with being HIV-negative, having con-
firmed TB and with a history of smoking.
Of the 103 patients who had spirometry performed after 2 months of TB treatment, only 34
(33.0%) had normal pulmonary function: 63 (61.2%) had restrictive deficit and 6 (5.8%) had
obstructive deficit. At 8 months, out of 33 patients who had restrictive pulmonary function at
2 months, 19 (57.6%) still had restrictive deficit; 4 had developed evidence of obstructive
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disease; and 10 had normal spirometry. Obstructive pulmonary function remained at 8
months in 3/4 who had had obstruction at 2 months. Of 21 patients who had normal spirome-
try initially, 2 developed obstruction and 1 developed restriction.
Drug toxicity
Overall 80/158 (50.6%) patients experienced at least one drug side effect during the first 2
months of retreatment, with streptomycin toxicity being common: ototoxicity developed in
35.9% and nephrotoxicity in 14.6%. Six patients (4.4%) developed drug induced liver injury,
and 51 (40.2%) reported symptoms of peripheral neuropathy.
Associations with clinical outcome on TB retreatment
The overall rate of successful treatment outcome in the cohort was 68.4%. Mortality was high
at 24.1%. In univariate analysis, baseline anaemia and systolic hypotension were both signifi-
cantly associated with poor end-of-treatment outcome (Table 2). After adjusting for age, gen-
der, HIV status, confirmed TB, hypotension, and anaemia, hypotension but not anaemia
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0215855.g001
Outcomes in recurrent tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0215855 May 6, 2019 5 / 13
Table 1. Baseline characteristics of study participants.
Total study population
n = 158
Patient age (median, IQR) 37 (31–43)
Patient sex (% male) 102 (64�6)
TB Class
Pulmonary 132 (83�5)
Extra-pulmonary 26 (16�5)
TB Category �
Relapse 62 (39�2)
TALTF 7 (4�4)
Fail 5 (3�2)
Other 84 (53�2)
No. of previous TB episodes
1 138 (87�3)
2 17 (10�8)
>2 3 (1�9)
HIV status
Negative 27 (17�1)
Positive 131 (82�9)
CD 4 count (median, IQR) 171 (61–324)
ART failure (n = 64) 24 (37�5)
Karnofsky score at baseline (median, IQR) 90 (80–100)
HR >100bpm 95 (60�1)
RR>20bpm 37 (23�4)
SBP<100mmHg 50 (31�7)
BMI
�18.5 36 (23�7)
16–18.4 75 (49�3)
<16 41 (27�0)
Anaemia 34 (22�2)
Diabetes 5 (3�3)
Renal impairment 52 (33�8)
Chronic Lung disease on CT Thorax (n = 102) 90 (88�2)
Pulmonary function testing (n = 103)
Normal 34 (33�0)
Obstructive 6 (5�8)
Restrictive 62 (61�2)
Smoker
Never 116 (73�4)
Former 41 (26�0)
Current 1 (0�6)
History of alcohol excess 27 (17�1)
� Relapse = a patient previously treated for TB, declared cured or treatment completed, who is diagnosed again with
smear or culture positive TB; Treatment after failure = a patient who is started on retreatment regimen after having
failed previous treatment; Treatment after loss to follow up (TALTF) = a patients who returns to treatment, positive
bacteriologically, following interruption of treatment for 2 or more consecutive months; Other previously
treated = all previously treated cases that do not fit any of the above definitions http://www.who.int/tb/err/rr_final_
forms_en.pdf.
https://doi.org/10.1371/journal.pone.0215855.t001
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Table 2. Features associated with clinical outcome on TB retreatment.
Successful outcome
n (%)
p-value OR (95% CI) p-value aOR (95% CI)�
Confirmed TB
No 47/66 (71.2 0.51 0.80 (0.40–1.58) 0.55 0.80 (0.37–1.70)
Yes 61/92 (66.3)
TB si
Pulmonary 93/132 (70.5) 0.20 0.57 (0.23–1.36) - -
Extra-pulmonary 15/26 (57.7)
TB Category
Relapse 47/63 (74.6)
TLTFU 5/7 (71.4) 0.86 0.85 (0.15–4.83) - -
Fail 3/5 (60.0) 0.48 0.51 (0.08–3.34) - -
Other 53/83 (63.9) 0.17 0.60 (0.29–1.24) - -
Age
<3 22/32 (68.8)
30–35 28/43 (65.1) 0.74 0.85 (0.32–2.25) 0.92 1.06 (0.36–3.11)
36–4 39/56 (69.6) 0.93 1.04 (0.41–2.67) 0.74 1.20 (0.40–3.57)
>45 19/27 (70.4) 0.89 1.08 (0.35–3.29) 0.85 1.12 (0.34–3.66)
Gender
Female 34/56 (60.7) 0.13 1.71 (0.86–3.41) 0.32 1.48 (0.69–3.20)
Male 74/102 (72.6)
HIV status
Negative 21/27 (77.8) 0.25 0.56 (0.21–1.50) 0.60 0.74 (0.24–2.30)
Positive 87/131 (66.4)
HR >100bp
No 47/63 (74.6) 0.17 0.61 (0.30–1.24) - -
Yes 61/95 (64.2)
RR>20bpm
No
Yes
64/95 (67.4)
44/63 (69.8)
0.74 -
1.12 (0.56–2.23)
- -
SBP<100mmHg
No 82/108 (95.9 0.003 0.34 (0.17–0.70) 0.02 0.41 (0.19–0.87)
Yes 26/50 (52.0)
BMI
�18.5 23/36 (63.9)
16–18.4 58/75 (77.3) 0.14 1.93 (0.81–4.60) - -
<16 24/41 (58.5) 0.63 0.80 (0.32–2.00) - -
Anaemia
No 88/119 (74.0) 0.02 0.40 (0.18–0.87) 0.11 0.50 (0.2.17)
Yes 18/34 (52.9)
Chronic Lung Disease on CT
No 11/12 (91.7) 0.32 0.34 (0.04–2.80) - -
Yes 71/90 (78.9)
Abnormal Spirometry
No 32/34 (94.1) 0.10 0.30 (0.06–1.27) - -
Yes 56/69 (81.2)
Diabetes
No 101/146 (69.2) 0.61 1.78 (0.19–16.4) - -
Yes 4/5 (80.0)
(Continued)
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remained significantly associated with outcome. Outcomes were worse in the categories ‘Fail’
and ‘Other’, but this difference was not statistically significant.
M. tuberculosis burden and drug sensitivity pattern
There was no association between infection with a drug-resistant isolate and unsuccessful clin-
ical outcome (OR 0.64, 95%CI 0.10–4.23; p-value 0.64). The median sputum culture time to
positivity (TTP) was 7.8 days (IQR 4.9–9.9 days), and there was no significant association
between TTP and clinical outcome (chi2 test for trend p-value 0.499).
HIV
Although the association was not statistically significant, it is of note that 66.4% of HIV-posi-
tive patients successfully completed treatment compared to 77.8% of HIV-negative patients.
Only 55.4% of patients with CD4 count <100 cells/mm3 successfully completed treatment
(OR 2.14, 95%CI 1.01–4.53; p-value 0.06). Patients with ART failure had only 50.0% chance of
successful treatment outcome, in comparison to 70.1% for patients without ART failure (OR
0.43, 95%CI 0.17–1.05; p-value 0.09).
Chronic lung disease
Table 3 demonstrates the probabilities of successful treatment outcome were non-significantly
lower for patients with any chronic lung disease, bronchiectasis, or scarring. Destroyed lung
was associated with unsuccessful clinical outcome on univariate analysis and after controlling
for age, gender, smoking, HIV and confirmed TB the adjusted OR for treatment success was
0.32 (95%CI 0.09–1.13).
Successful treatment outcome was seen in 52/63 (82.5%) of patients with restrictive deficit
on pulmonary function testing, in comparison to 36/40 (90.0%) without restrictive deficit (OR
0.52, 95%CI 0.15–1.78; p-value 0.39). Of 6 patients who had obstructive pulmonary deficit,
only 4 (66.7%) had successful treatment outcome compared to those without obstruction in
whom 84/97 (86.6%) successfully completed treatment (OR 0.31, 95%CI 0.05–1.86; p-value
0.21).
Drug toxicity
There were no significant associations between treatment outcome and nephrotoxicity or oto-
toxicity (Table 4). Four out of six patients with drug induced liver injury died (RR 5.78, 95%CI
2.75–12.10; p-value 0.004).
Table 2. (Continued)
Successful outcome
n (%)
p-value OR (95% CI) p-value aOR (95% CI)�
Renal impairment
No 74/102 (72.5) 0.11 0.56 (0.28–1.13) -
Yes 31/52 (59.6)
� adjusted for age, gender, HIV, confirmed TB, hypotension, anaemia
https://doi.org/10.1371/journal.pone.0215855.t002
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Discussion
This study confirms once again that outcomes in patients receiving recurrent courses of TB
treatment are poor with only 68.4% of patients successfully completing treatment. Despite no
rifampicin resistance in this cohort, outcomes were no better than those reported for the treat-
ment of MDR-TB in many other cohorts [21]. More importantly, these data also provide new
insights into reasons which may explain poor outcomes in patients with retreatment
tuberculosis.
In contrast to studies of patients presenting with a first TB episode, neither microbiologi-
cally confirmed TB nor TB burden (as estimated by TTP) were predictive of clinical outcome
[22–23] in patients entering care having previously received TB treatment. The difference in
outcomes between those with and without confirmed TB has previously been ascribed primar-
ily to the fact that patients treated empirically for tuberculosis may not have TB, but rather
Table 4. Drug toxicity on TB retreatment.
Total
n (%)
Successful outcome without toxicity
n (%)
Successful outcome with toxicity
n (%)
p-value OR
Ototoxicity 28/78 (35.9) 43/50 (86.0) 23/28 (82.1) 0.65 0.75
(0.21–2.63)
Nephrotoxicity 19/130 (14.6) 88/111 (79.3) 15/19 (79.0) 0.97 0.98
(0.30–3.24)
Neuropathy 51/127 (40.2) 62/76 (81.6) 40/51 (78.4) 0.66 0.82
(0.34–1.99)
DILI 6/136 (4.4) 104/130 (80.0) 2/6 (33.3) 0.02 0.13
(0.02–6.15)
SJS 1/158 (0.6) 107/157 (68.2) 1/1 (100.0) 1.0 -
DILI = Drug Induced Liver Injury
SJS = Stevens Johnson Syndrome
https://doi.org/10.1371/journal.pone.0215855.t004
Table 3. Chronic lung disease and TB retreatment outcomes.
Successful outcome
n (%)
p-value OR p-value aOR�
Any CLD
No 11/12 (91.7) 0.32 0.34 (0.04–2.80) 0.24 0.26 (0.03–2.45)
Yes 71/90 (78.9)
Bronchiectasis
No 35/40 (0.88) 0.15 0.45 (0.15–1.35) 0.17 0.41 (0.19–1.47)
Yes 47/62 (0.76)
Emphysema
No 64/80 (0.80) 0.85 1.13 (0.33–3.79) 0.91 0.93 (0.25–3.42)
Yes 18/22 (0.82)
Destroyed lung
No 70/83 (0.84) 0.04 0.32 (0.11–0.96) 0.08 0.32 (0.09–1.13)
Yes 12/19 (0.63)
Scarring
No 18/20 (0.90) 0.24 0.40 (0.08–1.86) 0.09 0.23 (0.04–1.28)
Yes 64/82 (0.78)
� Adjusted for age, gender, smoking, HIV, onfirmed TB
https://doi.org/10.1371/journal.pone.0215855.t003
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have other conditions (such as bronchiectasis, cancer or P. jerovecii) which remain undiag-
nosed and therefore untreated [24]. A possible explanation for the discrepant result in this
study is that, compared to new patients, there is a high prevalence of multiple concurrent diag-
noses in patients with retreatment TB regardless of whether they have confirmed tuberculosis;
and that co-morbid disease is therefore contributing to unsuccessful treatment in all sub-
groups of previously treated patients.
Unlike some countries with a high TB incidence, Malawi has a low prevalence of drug resis-
tant tuberculosis [25], which was shown again in this study. The 0.096 prevalence of drug resis-
tance cannot explain why 31.6% of patients did not complete treatment. If neither
microbiologically confirmed TB, high mycobacterial burden, nor drug resistance are account-
ing for poor outcomes on TB retreatment in this setting, it is probable that other, non-TB, fac-
tors are.
The prevalence of medical co-morbidities was indeed extremely high, with 82.9% of
patients being HIV infected, 88.2% having chronic lung disease on CT thorax, 33.8% having
baseline renal impairment, and 22.2% having anaemia. The study was not powered to detect
associations between these factors and clinical outcome, however the proportion successfully
completing treatment was non-significantly lower for patients with HIV (66.4% v 77.8%);
chronic lung disease (78.9% v 91.7%); renal impairment (59.6% v 72.5%); and anaemia (52.9%
v 74.0%).
The prevalence of HIV in this cohort with retreatment TB was 82.9%, higher than the
reported 56% prevalence in adults with TB in Malawi [20], and the high proportion of patients
with ART failure is a major concern. It is possible that ART failure is common in patients on
TB retreatment because this is a group in whom adherence to ART and TB drugs is poor, put-
ting them at risk of both ART failure and retreatment TB. However, people established on
ART can live for decades but remain at increased risk of TB throughout that time, thereby
increasing their chances of having more than one TB episode. As more people are initiated on
HIV treatment in settings with high TB transmission, a growing pool of HIV-positive people
living for many years on ART, and therefore at risk of both TB retreatment and ART failure,
may develop.
Of interest is the very high burden of chronic lung disease in patients on TB retreatment,
and the clear suggestion that this contributes to poor outcomes. The fact that spirometry was
performed only on patients who survived to 2-months may mean that the prevalence of lung
disease may even have been underestimated. Previous literature had gone some way to
describe the features of post-tuberculous lung disease, however none has specifically assessed
the burden of lung disease in patients entering care at the point of a retreatment episode [26–
27]. If the vast majority of patients starting TB retreatment have underlying chronic lung dis-
ease, it is probable that simply treating their respiratory disease with anti-tuberculous drugs
will not be sufficient.
After adjusting for age, gender and HIV status the only factor associated with unsuccessful
treatment outcome was hypotension at presentation. There are a number of explanations for
this association including late presentation with advanced disease [28–29], concurrent bacte-
rial sepsis [30] and hypoadrenalism [31].
The incidence of drug toxicity during the first two months of treatment was high, with
50.6% of all patients experiencing at least one drug side effect. The incidence of streptomycin
induced toxicity is of particular concern as 35.0% of patients developed ototoxicity and 14.6%
developed nephrotoxicity. Whilst these side effects were not associated with outcome, the high
rates are likely to be associated with significant morbidity. This cohort provides the first data
on the incidence of streptomycin toxicity in an African cohort on Category II regimen, and
adds further weight to the move away from routine use of the regimen.
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A weakness of the study is that it was not powered to detect associations between outcome
and potential explanatory variables. Hence, whilst it was possible to demonstrate high preva-
lence of co-morbidity and high incidence of toxicity, the study was frequently unable to show
these were statistically associated with outcome. A second drawback is that the study did not
recruit a control group and instead comparisons are made to published data. Finally, due to
practical and ethical considerations, post mortem examinations were not performed, preclud-
ing the establishment of exact cause of death for those who died. Nevertheless, the complexity
of the clinical issues facing this very heterogeneous group of patients is highlighted, both in
terms of prevalence and severity, and it seems unlikely that such a high burden of comorbid
disease is not contributing to poor outcomes.
Overall, this study demonstrates that there may be multiple explanations for the poor clini-
cal outcomes consistently seen in patients who register for TB treatment having previously
been treated. The WHO post-2015 strategy for tuberculosis has set a target of 95% reduction
in TB deaths by 2035. If these targets are to be met and morbidity and mortality associated
with retreatment TB reduced, the TB community must adopt a broader approach to the spe-
cific problems faced by patients with retreatment TB. Key issues which need to be addressed
include the broad clinical management of patients who present with acute severe illness and
hypotension; diagnosis and treatment of non-MDR drug resistance; prevention of drug toxic-
ity; and management of medical co-morbidity especially HIV and chronic lung damage.
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